artificial intelligence (AI)

BrightHeart will officially introduce the platform to European clinicians during the Fetal Medicine Foundation (FMF) World Congress in Vienna, taking place from June 28 to July 2, 2026.

Moscow researchers developed a series of national standards, known as GOST standards, covering the creation, testing, and clinical use of AI technologies.

The analysis showed that the best results were achieved when AI acted as a “second reader,” supporting physicians rather than replacing them.

The agreement brings together Protillion’s computational biology platform with Merck’s established drug development expertise to support the discovery of next-generation therapies.

The publications aim to support the growing integration of AI into medical imaging and to strengthen clinicians’ ability to use these technologies safely and effectively in everyday practice.

Since 2020, the Moscow government has been running the Moscow Experiment on Computer Vision in healthcare, an initiative coordinated by the Center for Diagnostics and Telemedicine with support from the city’s digital infrastructure teams.

The initiative integrates Johnson & Johnson’s Polyphonic™ open digital ecosystem with DOH Abu Dhabi and leading technology partners, including Amazon Web Services (AWS) and NVIDIA.

The company will present its newly CE-marked AI contouring solution at the annual congress of the European Society for Radiotherapy and Oncology in Stockholm.

Isomorphic Labs plans to use the new capital to further develop and deploy its proprietary AI drug design engine, known as IsoDDE.

Built on the Mayo Clinic Platform, the system operates within a secure environment where Mayo Clinic teams can access large volumes of de-identified patient data.